Glomerulonephritis Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Glomerulonephritis Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The glomerulonephritis market size has experienced consistent expansion in recent years. This market is set to increase from $11.06 billion in 2024 to $11.61 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.9%. The market’s growth during the preceding period is largely due to factors such as the increasing occurrence of kidney disorders, the commonness of infections including post-streptococcal glomerulonephritis, an escalation in research and development activities, a rise in the incidence of kidney failure, and enhanced public knowledge about kidney diseases.

The glomerulonephritis market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $14.03 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 4.9%. Factors contributing to this growth during the forecast period include a rise in diabetes cases, an expanding elderly demographic, greater investments in healthcare spending, an increase in individuals undergoing dialysis, and a growing prevalence of autoimmune conditions. Key trends anticipated within this period encompass the introduction of new treatments and therapies, advancements in diagnostic technologies, innovative therapeutic approaches, increased collaboration among companies, and the utilization of intravenous immunoglobulin therapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

Which Drivers Are Impacting The Glomerulonephritis Market?

The glomerulonephritis market is anticipated to grow as a result of the increasing prevalence of kidney disorders. Kidney disorders encompass a variety of conditions that impact the kidneys’ structure or function, leading to impaired filtration, waste removal, and fluid balance. The rising occurrence of kidney disorders can be linked to factors such as an aging demographic, escalating rates of chronic diseases like diabetes and hypertension, and lifestyle choices. These disorders contribute to glomerulonephritis by triggering immune system irregularities, chronic inflammation, or structural damage, which subsequently hinders kidney filtration and function. As an illustration, in December 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that chronic kidney disease (CKD) mortality rates saw increases of 4.2% in 2021 and 6.2% in 2022. Additionally, during 2021–22, CKD was identified in around 2 million hospitalizations, representing 18% of all hospitalizations in Australia. Consequently, the growing incidence of kidney disorders will act as a driving force for the expansion of the glomerulonephritis market.

What Are The Different Segment Classifications Within The Glomerulonephritis Market?

The glomerulonephritismarket covered in this report is segmented –

1) By Type: Acute Glomerulonephritis; Chronic Glomerulonephritis

2) By Diagnosis: Urine And Blood Tests; Imaging Tests; Kidney Biopsy; Other Diagnosis

3) By Treatment: Medication; Surgery; Dialysis; Other Treatments

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Specialty Clinics; Other End-Users

Subsegments:

1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis; IgA Nephropathy; Lupus Nephritis; Rapidly Progressive Glomerulonephritis (RPGN); Goodpasture Syndrome

2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS); Membranous Nephropathy; Minimal Change Disease; Alport Syndrome; Diabetic Nephropathy; Hypertensive Nephrosclerosis

How Are Trends Influencing The Glomerulonephritis Market?

Leading companies in the glomerulonephritis market are concentrating on developing innovative non-immunosuppressive treatments to fill medical gaps and enhance patient well-being. Non-immunosuppressive treatments are therapies designed to manage conditions without diminishing or suppressing the immune system, thereby preserving immune function. For instance, in September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, introduced FILSPARI (sparsentan), which received approval from the Food and Drug Administration (FDA) for the treatment of IgA nephropathy, a specific kidney disease. This medication is unique as the only non-immunosuppressive treatment shown to significantly reduce the rate of kidney function decline in affected patients. The approval of FILSPARI represents a substantial advancement in the management of IgA nephropathy, which is identified as the most prevalent form of primary glomerulonephritis. This therapy offers a novel alternative for patients who previously had restricted treatment options. The authorization underscores Travere’s dedication to improving patient outcomes in kidney disease.

Who Are The Key Multinational Companies Dominating The Glomerulonephritis Market?

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

Which Geographies Are Emerging As Strong Markets For The Glomerulonephritis Industry?

North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Glomerulonephritis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp

Browse Through More Reports Similar to the Global Glomerulonephritis Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Hospital Acquired Infections Testing Kits Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795